Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics (NQ: NKTR )

1.570 -0.100 (-5.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,847,284
Open 1.680
Bid (Size) 1.550 (1)
Ask (Size) 1.610 (1)
Prev. Close 1.670
Today's Range 1.500 - 1.690
52wk Range 0.4126 - 1.750
Shares Outstanding 183,801,441
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Nektar Therapeutics commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin, in patients with severe to very severe alopecia areata, a disease-causing patchy hair... 
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal

Performance

YTD
+163.95%
+163.95%
1 Month
+84.71%
+84.71%
3 Month
+204.26%
+204.26%
6 Month
+197.91%
+197.91%
1 Year
+59.70%
+59.70%

More News

Read More
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Nektar Therapeutics Earnings Preview
Via Benzinga
Recap: Nektar Therapeutics Q3 Earnings
Via Benzinga
Earnings Scheduled For March 4, 2024
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
A Preview Of Nektar Therapeutics's Earnings
Via Benzinga
The One-Minute Market Report - Saturday, Aug. 12
Via Talk Markets
Topics ETFs
Expert Ratings for Nektar Therapeutics
Via Benzinga
Nektar Therapeutics: Q1 Earnings Insights
Via Benzinga
Analyst Ratings for Nektar Therapeutics
Via Benzinga
Nektar Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Is Nektar Therapeutics Stock Surging Today?
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Tempur Sealy International To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
Via Benzinga
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
Via InvestorPlace
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.